Xavier Paoletti

List of Publications by Year
in descending order

104 papers	5,211 citations	117619 34 h-index	88628 70 g-index
110 all docs	110 docs citations	110 times ranked	7860 citing authors

#	Article	IF	Citations
1	Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncology, The, 2015, 16, 1324-1334.	10.7	897
2	Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer. JAMA - Journal of the American Medical Association, 2010, 303, 1729.	7.4	711
3	EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Science Translational Medicine, 2014, 6, 244ra91.	12.4	304
4	Emergency circulatory support in refractory cardiogenic shock patients in remote institutions: a pilot study (the cardiac-RESCUE program). European Heart Journal, 2013, 34, 112-120.	2.2	239
5	Successful long-term program for controlling methicillin-resistant Staphylococcus aureus in intensive care units. Intensive Care Medicine, 2005, 31, 1051-1057.	8.2	139
6	Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro-Oncology, 2011, 13, 109-118.	1.2	137
7	Disease-Free Survival as a Surrogate for Overall Survival in Adjuvant Trials of Gastric Cancer: A Meta-Analysis. Journal of the National Cancer Institute, 2013, 105, 1600-1607.	6.3	133
8	Phase I Trials of Molecularly Targeted Agents: Should We Pay More Attention to Late Toxicities?. Journal of Clinical Oncology, 2011, 29, 1728-1735.	1.6	120
9	Leukocyte activation: The link between inflammation and coagulation during heatstroke. A study of patients during the 2003 heat wave in Paris*. Critical Care Medicine, 2008, 36, 2288-2295.	0.9	110
10	Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents â€“ Dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study. European Journal of Cancer, 2014, 50, 2040-2049.	2.8	104
11	Statistical evaluation of surrogate endpoints with examples from cancer clinical trials. Biometrical Journal, 2016, 58, 104-132.	1.0	93
12	Non-parametric optimal design in dose finding studies. Biostatistics, 2002, 3, 51-56.	1.5	91
13	Operating characteristics of the standard phase I clinical trial design. Computational Statistics and Data Analysis, 1999, 30, 303-315.	1.2	86
14	Utilityâ€Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials. Biometrics, 2010, 66, 532-540.	1.4	78
15	Progression-Free Survival as a Surrogate for Overall Survival in Advanced/Recurrent Gastric Cancer Trials: A Meta-Analysis. Journal of the National Cancer Institute, 2013, 105, 1667-1670.	6.3	78
16	Continual Reassessment Method for Ordered Groups. Biometrics, 2003, 59, 430-440.	1.4	77
17	Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials. Journal of the National Cancer Institute, 2016, 108, djv362.	6.3	71
18	Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: Results of a DLT-TARGETT international survey. European Journal of Cancer, 2014, 50, 2050-2056.	2.8	63

#	Article	IF	Citations
19	Regulation of peritoneal and systemic neutrophil-derived tumor necrosis factor-Î± release in patients with severe peritonitis: Role of tumor necrosis factor-Î± converting enzyme cleavage*. Critical Care Medicine, 2005, 33, 1359-1364.	0.9	61
20	Early phase clinical trials of anticancer agents in children and adolescents â€" an ITCC perspective. Nature Reviews Clinical Oncology, 2017, 14, 497-507.	27.6	61
21	Outcome of children with relapsed or refractory neuroblastoma: A metaâ€anâ€analysis of ITCC/SIOPEN European phase II clinical trials. Pediatric Blood and Cancer, 2017, 64, 25-31.	1.5	61
22	Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials. Quality of Life Research, 2008, 17, 831-843.	3.1	60
23	The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma. Journal of Hepatology, 2013, 58, 509-521.	3.7	60
24	Precision medicine needs randomized clinical trials. Nature Reviews Clinical Oncology, 2017, 14, 317-323.	27.6	60
25	Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents. Targeted Oncology, 2010, 5, 65-72.	3.6	58
26	Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial. Targeted Oncology, 2012, 7, 253-265.	3.6	57
27	Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials. Annals of Oncology, 2015, 26, 1808-1812.	1.2	55
28	A comparative analysis of paediatric dose-finding trials of molecularly targeted agent with adultsâ€™ trials. European Journal of Cancer, 2013, 49, 2392-2402.	2.8	51
29	Design efficiency in dose finding studies. Computational Statistics and Data Analysis, 2004, 45, 197-214.	1.2	47
30	A Meta-Analysis of the Relationship between FGFR3 and TP53 Mutations in Bladder Cancer. PLoS ONE, 2012, 7, e48993.	2.5	47
31	Breast cancer risk in relation to abortion: Results from the EPIC study. International Journal of Cancer, 2006, 119, 1741-1745.	5.1	43
32	Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer. JAMA Network Open, 2020, 3, e1918939.	5.9	40
33	Sensitivity Analysis When Data Are Missing Not-at-random. Epidemiology, 2011, 22, 282.	2.7	39
34	Efficiency of New Dose Escalation Designs in Dose-Finding Phase I Trials of Molecularly Targeted Agents. PLoS ONE, 2012, 7, e51039.	2.5	39
35	Using the continual reassessment method: Lessons Learned from an EORTC phase I dose finding study. European Journal of Cancer, 2006, 42, 1362-1368.	2.8	37
36	Characteristics and Outcome of SARS-CoV-2 Infection in Cancer Patients. JNCI Cancer Spectrum, 2021, 5, pkaa090.	2.9	37

#	Article	IF	Citations
37	Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSÃ©-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium. European Journal of Cancer, 2021, 150, 53-62.	2.8	33
38	Innovations for phase I dose-finding designs in pediatric oncology clinical trials. Contemporary Clinical Trials, 2016, 47, 217-227.	1.8	29
39	surrosurv: An R package for the evaluation of failure time surrogate endpoints in individual patient data meta-analyses of randomized clinical trials. Computer Methods and Programs in Biomedicine, 2018, 155, 189-198.	4.7	29
40	Tension-Free Vaginal Tape and Associated Procedures: A Case Control Study. European Urology, 2004, 45, 356-361.	1.9	28
41	Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting. Journal of Hepatology, 2011, 54, 108-114.	3.7	27
42	Doseâ€finding design using mixedâ€effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials. Statistics in Medicine, 2013, 32, 5430-5447.	1.6	26
43	The International Collaboration for Research methods Development in Oncology (CReDO) workshops: shaping the future of global oncology research. Lancet Oncology, The, 2021, 22, e369-e376.	10.7	25
44	Development of anti-cancer drugs. Discovery Medicine, 2010, 10, 355-62.	0.5	24
45	Methodological Development of Combination Drug and Radiotherapy in Basic and Clinical Research. Clinical Cancer Research, 2020, 26, 4723-4736.	7.0	23
46	Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer. Investigational New Drugs, 2003, 21, 347-352.	2.6	22
47	Impaired Smooth Pursuit in Schizophrenia Results from Prediction Impairment Only. Biological Psychiatry, 2010, 67, 992-997.	1.3	22
48	Clinical impact of low-volume lymph node metastases in early-stage cervical cancer: A comprehensive meta-analysis. Gynecologic Oncology, 2022, 164, 446-454.	1.4	22
49	Patient-reported tolerability of adverse events in phase 1 trials. ESMO Open, 2017, 2, e000148.	4.5	20
50	Induced and spontaneous abortion and breast cancer risk: Results from the E3N cohort study. International Journal of Cancer, 2003, 106, 270-276.	5.1	19
51	Critical Evaluation of Disease Stabilization As a Measure of Activity of Systemic Therapy: Lessons From Trials With Arms in Which Patients Do Not Receive Active Treatment. Journal of Clinical Oncology, 2014, 32, 260-263.	1.6	19
52	Has tumor doubling time in breast cancer changed over the past 80 years? A systematic review. Cancer Medicine, 2021, 10, 5203-5217.	2.8	19
53	First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSÃ©-ESMART trial. European Journal of Cancer, 2021, 157, 268-277.	2.8	19
54	Multiple recurrences and risk of disease progression in patients with primary low-grade (TaG1) nonâ€“muscle-invasive bladder cancer and with low and intermediate EORTC-risk score. PLoS ONE, 2019, 14, e0211721.	2.5	17

#	Article	IF	Citations
55	Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSÃ©-ESMART Trial. Journal of Clinical Oncology, 2021, 39, 3546-3560.	1.6	17
56	Risks and benefits of anticancer drugs in advanced cancer patients: A systematic review and meta-analysis. EClinicalMedicine, 2021, 40, 101130.	7.1	16
57	Serious psychiatric outcome of subjects prenatally exposed to diethylstilboestrol in the E3N cohort study. Psychological Medicine, 2007, 37, 1315-1322.	4.5	15
58	The spectrum of clinical trials aiming at personalizing medicine. Chinese Clinical Oncology, 2014, 3, 13.	1.2	15
59	Dose finding with longitudinal data: simpler models, richer outcomes. Statistics in Medicine, 2015, 34, 2983-2998.	1.6	13
60	Precision medicine: lessons learned from the SHIVA trial â€“ Authors' reply. Lancet Oncology, The, 2015, 16, e581-e582.	10.7	13
61	Optimal Cut Points for Quality of Life Questionnaire-Core 30 (QLQ-C30) Scales: Utility for Clinical Trials and Updates of Prognostic Systems in Advanced Hepatocellular Carcinoma. Oncologist, 2015, 20, 62-71.	3.7	13
62	Long-term follow-up of TaG1 nonâ€“muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 20.e1-20.e7.	1.6	13
63	A benchmark for dose finding studies with continuous outcomes. Biostatistics, 2020, 21, 189-201.	1.5	13
64	Survival analysis in clinical trials: Old tools or new techniques. Surgical Oncology, 2010, 19, 55-58.	1.6	12
65	A Poisson approach to the validation of failure time surrogate endpoints in individual patient data meta-analyses. Statistical Methods in Medical Research, 2019, 28, 170-183.	1.5	12
66	Quantitative CT Extent of Lung Damage in COVID-19 Pneumonia Is an Independent Risk Factor for Inpatient Mortality in a Population of Cancer Patients: A Prospective Study. Frontiers in Oncology, 2020, 10, 1560.	2.8	12
67	Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis. Future Oncology, 2021, 17, 1811-1823.	2.4	12
68	Phase Iâ€“II trial designs: how early should efficacy guide the dose recommendation process?. Annals of Oncology, 2018, 29, 540-541.	1.2	11
69	Randomized dose-escalation designs for drug combination cancer trials with immunotherapy. Journal of Biopharmaceutical Statistics, 2019, 29, 359-377.	0.8	11
70	Predictive Gene Signature of Response to the Anti-TweakR mAb PDL192 in Patient-Derived Breast Cancer Xenografts. PLoS ONE, 2014, 9, e104227.	2.5	10
71	Prognostic factors of successful on-purpose tumor biopsies in metastatic cancer patients included in the SHIVA prospective clinical trial. Oncotarget, 2017, 8, 1760-1773.	1.8	10
72	Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treatment Reviews, 2007, 33, 762-763.	7.7	9

#	Article	IF	Citations
73	An explorative study to assess the association between health-related quality of life and the recommended phase II dose in a phase I trial: idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma. BMJ Open, 2016, 6, e010696.	1.9	9
74	A benchmark for dose-finding studies with unknown ordering. Biostatistics, 2022, 23, 721-737.	1.5	9
75	Shelf Life of Predosed Plates Containing Mefloquine, Artemisinin, Dihydroartemisinin, and Artesunate as Used for In Vitro Plasmodium falciparum Susceptibility Assessment. Journal of Clinical Microbiology, 2007, 45, 2734-2736.	3.9	8
76	np1: A computer program for dose escalation strategies in phase I clinical trials. Computer Methods and Programs in Biomedicine, 2007, 88, 8-17.	4.7	8
77	Challenges for the implementation of high-throughput testing and liquid biopsies in personalized medicine cancer trials. Personalized Medicine, 2014, 11, 545-558.	1.5	8
78	Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data. Clinical Trials, 2017, 14, 611-620.	1.6	7
79	Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?. British Journal of Cancer, 2018, 119, 937-939.	6.4	7
80	Sequential or combined designs for Phase I/II clinical trials? A simulation study. Clinical Trials, 2019, 16, 635-644.	1.6	7
81	Operating characteristics of two independent sample design in phase I trials in paediatric oncology. European Journal of Cancer, 2010, 46, 1392-1398.	2.8	6
82	Cumulative Toxicity in Targeted Therapies: What to Expect at the Recommended Phase II Dose. Journal of the National Cancer Institute, 2019, 111, 1179-1185.	6.3	6
83	An adaptive design for the identification of the optimal dose using joint modeling of continuous repeated biomarker measurements and time-to-toxicity in phase I/II clinical trials in oncology. Statistical Methods in Medical Research, 2020, 29, 508-521.	1.5	6
84	Dose-Finding Methods: Moving Away from the 3 + 3 to Include Richer Outcomes. Clinical Cancer Research, 2017, 23, 3977-3979.	7.0	4
85	Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium. European Journal of Cancer, 2017, 86, 275-284.	2.8	4
86	Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials. Investigational New Drugs, 2018, 36, 62-74.	2.6	3
87	A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation. Clinical Trials, 2020, 17, 522-534.	1.6	3
88	Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee. Gynecologic Oncology, 2021, 161, 502-507.	1.4	3
89	Using a new diagnostic tool to predict lymph node metastasis in advanced epithelial ovarian cancer leads to simple lymphadenectomy decision rules: A multicentre study from the FRANCOGYN group. PLoS ONE, 2021, 16, e0258783.	2.5	3
90	Re: Clinical Characteristics and Outcomes of COVID-19â€“Infected Cancer Patients: A Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 2021, 113, 342-343.	6.3	2

#	Article	IF	Citations
91	Meta-analysis of prognostic and predictive factors: TowardsÂindividual participant data?. European Journal of Cancer, 2018, 104, 224-226.	2.8	1
92	An alternative trial-level measure for evaluating failure-time surrogate endpoints based on prediction error. Contemporary Clinical Trials Communications, 2019, 15, 100402.	1.1	1
93	Using a doseâ€finding benchmark to quantify the loss incurred by dichotomization in Phase II doseâ€ranging studies. Biometrical Journal, 2020, 62, 1717-1729.	1.0	1
94	Changeâ€point joint model for identification of plateau of activity in early phase trials. Statistics in Medicine, 2021, 40, 2113-2138.	1.6	1
95	Acute and late toxicities of patients infected with SARS-CoV-2 and treated for cancer with radiation therapy during the COVID-19 pandemic. International Journal of Radiation Biology, 2021, 97, 1436-1440.	1.8	1
96	Design and statistical principles of the SHIVA trial. Chinese Clinical Oncology, 2015, 4, 32.	1.2	1
97	Evaluation of Surrogate Endpoints Using a Meta-Analysis Approach with Individual Patient Data: Summary of a Gastric Cancer Meta-Analysis Project. , 2017, , 179-192.		0
98	Evaluating Personalized Medicine in Multi-marker Multi-treatment Clinical Trials: Accounting for Heterogeneity. , 2017, , 125-149.		0
99	Proportional odds assumption for modeling longitudinal ordinal multiple toxicity outcomes in dose finding studies of targeted agents: A pooled analysis of 54 studies. Contemporary Clinical Trials Communications, 2020, 17, 100529.	1.1	0
100	Dose Finding Methods in Oncology: From the Maximum Tolerated Dose to the Recommended Phase II Dose. , 2014, , 335-361.		0
101	Designs for Evaluating Precision Medicine Trials. , 2015, , 113-131.		0
102	Statistical Designs for First-in-Man Phase I Cancer Trials. , 2015, , 171-200.		0
103	Statistical Evaluation of Surrogate Endpoints in Cancer Clinical Trials. , 2018, , .		0
104	Why Do Clinical Trials Fail?. , 2018, , .		0